PYY, a Therapeutic Option for Type 2 Diabetes?
- PMID: 32030069
- PMCID: PMC6977199
- DOI: 10.1177/1179551419892985
PYY, a Therapeutic Option for Type 2 Diabetes?
Abstract
Metabolic surgery leads to rapid and effective diabetes reversal in humans, by weight-independent mechanisms. The crucial improvement in pancreatic islet function observed after surgery is induced by alteration in several factors, including gut hormones. In addition to glucagon-like peptide 1 (GLP-1), increasing lines of evidence show that peptide tyrosine tyrosine (PYY) plays a key role in the metabolic benefits associated with the surgery, ranging from appetite regulation to amelioration of islet secretory properties and survival. Here, we summarize the current knowledge and the latest advancements in the field, which pitch a strong case for the development of novel PYY-based therapy for the treatment of diabetes.
Keywords: PYY; bariatric surgery; diabetes; pancreatic islets.
© The Author(s) 2020.
Conflict of interest statement
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References
-
- Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012;303:E122-E131. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
